Heyman, Benjamin <br/><br/>
Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.  [electronic resource] 

 -  Clinical lymphoma, myeloma & leukemia  10 2018 
 - 679-686 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2152-2669 
<br/><br/><label>Standard No.: </label>10.1016/j.clml.2018.07.285  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bendamustine Hydrochloride--administration & dosage<br/>Drug Resistance, Neoplasm--drug effects<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Isoquinolines--administration & dosage<br/>Lymphoma, B-Cell--drug therapy<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Prognosis<br/>Prospective Studies<br/>Rituximab--administration & dosage<br/>Salvage Therapy<br/>Survival Rate